Cubist Systematic Strategies, LLC Checkpoint Therapeutics, Inc. Transaction History

Cubist Systematic Strategies, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.97 - $1.77 $90,999 - $166,050	-93,814 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.53 - $3.25 $38,118 - $80,970	24,914 Added 36.16%	93,814 $166,000
Q4 2021 Feb 14, 2022	BUY	$2.68 - $4.46 $184,652 - $307,294	68,900 New	68,900 $214,000
Q3 2021 Nov 15, 2021	SELL	$2.5 - $3.53 $33,347 - $47,086	-13,339 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$2.36 - $3.2 $31,480 - $42,684	13,339 New	13,339 $39,000
Q4 2020 Feb 16, 2021	SELL	$2.19 - $2.96 $40,622 - $54,905	-18,549 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$1.62 - $4.24 $30,049 - $78,647	18,549 New	18,549 $50,000

1.91M

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $290M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.